William Frank Iv Hulse Sells 54,596 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock

MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) CAO William Frank Iv Hulse sold 54,596 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $430,762.44. Following the transaction, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at $3,473,004.42. This represents a 11.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

William Frank Iv Hulse also recently made the following trade(s):

• On Monday, March 10th, William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock. The shares were sold at an average price of $7.80, for a total transaction of $635,278.80.

MiMedx Group Stock Down 1.5 %

Shares of MDXG traded down $0.12 on Tuesday, hitting $7.92. 366,929 shares of the stock traded hands, compared to its average volume of 696,579. The company has a market capitalization of $1.17 billion, a PE ratio of 14.40 and a beta of 1.97. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The business has a 50 day simple moving average of $8.44 and a 200 day simple moving average of $7.83. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. As a group, equities analysts forecast that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC boosted its stake in shares of MiMedx Group by 133.6% during the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock worth $1,806,000 after acquiring an additional 174,797 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of MiMedx Group by 265.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock worth $1,757,000 after acquiring an additional 215,995 shares during the last quarter. Barclays PLC boosted its stake in shares of MiMedx Group by 163.9% during the 3rd quarter. Barclays PLC now owns 262,449 shares of the company's stock worth $1,550,000 after acquiring an additional 163,005 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of MiMedx Group by 79.9% during the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock worth $802,000 after acquiring an additional 37,031 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of MiMedx Group by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock worth $328,000 after acquiring an additional 3,292 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.